ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1208

Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum

Georgina Nakafero1, Matthew J. Grainge1, Tim Card1, Maarten W Taal1, Guruprasad P Aithal1, Christopher P Fox2, Christian Mallen3, Danielle van der Windt3, Richard Riley3 and Abhishek Abhishek1, 1University of Nottingham, Nottingham, United Kingdom, 2Nottingham University Hospital NHS Trust, Nottingham, United Kingdom, 3Keele University, Keele, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, Disease-Modifying Antirheumatic Drugs (Dmards), Epidemiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients established on long-term low-dose weekly methotrexate treatment undergo 3-monthly monitoring blood-tests to facilitate early detection of drug-related adverse events. Regular testing may not be necessary for those at low risk whereas patients at high-risk may require more frequent monitoring or be prescribed alternate drugs. Thus, the aim of this study was to develop and externally validate a prognostic model for methotrexate discontinuation with abnormal blood-test results that can be used to inform clinical practice.

Methods: Data from Clinical Practice Research Datalink (CPRD) Gold and Aurum were used for model development and external validation respectively. CPRD Gold and Aurum have complementary coverage of GP practices, and this allowed for true external validation. Patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriasis +/- arthritis, connective tissue disease etc. prescribed methotrexate between 01/01/2007 and 31/12/2019 were followed-up from six-months after their first shared-care GP-prescription to the earliest of outcome date, death date, 5-year follow-up or 31/12/2019. Multiple imputation was applied to handle missing data. All candidate predictors were included in the Cox model. The equation for predicting an individual’s risk of methotrexate discontinuation at 5-years was formulated. Internal validation using 500-bootstrap samples was undertaken to correct for optimism. Regression coefficients were penalised using the uniform shrinkage factor, estimated as the average of calibration slopes from each of the bootstrap samples. Model performance was assessed in terms of calibration and discrimination.

Results: Data for 13,110 and 23,999 participants were included in the development and validation cohorts, respectively. Majority of participants in the development and validation cohort were female; 63.1% vs. 63.6%, had rheumatoid arthritis; 61.8% vs.62.8% and had comparable prevalence of adverse lifestyle factors, comorbidities, and prescriptions. Diabetes, chronic kidney disease and mild cytopenia or elevated liver enzymes during the six-month of methotrexate prescription prior to start of follow-up were strong predictors of drug discontinuation with adjusted hazard ratio (95% confidence interval (CI)) 1.25 (1.02-1.53), 2.01 (1.63-2.49) and 2.97 (2.57-3.41) respectively (Table 1).

The baseline survival function was 0.895 and uniform shrinkage factor was 0.93 used to calculate methotrexate discontinuation risk score (Figure 1). The optimism unadjusted and adjusted calibration slope (95% CI) in development data was 1.00 (0.89-1.11) and 0.93 (0.82- 1.04) respectively. The calibration slope (95% CI) in validation data was 0.94 (0.85- 1.02) (Figure 2). The model showed prognostic separation with Royston D statistic (95%CI) of 0.79 (0.69-0.90) and 0.75 (0.67-0.83) in the development and external validation data respectively.

Conclusion: This prognostic model used predictors available during routine clinical consultations and should be used to risk-stratify blood-test monitoring after the first year of methotrexate prescription.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. Nakafero, None; M. Grainge, None; T. Card, None; M. Taal, None; G. Aithal, AstraZeneca; C. Fox, None; C. Mallen, None; D. van der Windt, None; R. Riley, None; A. Abhishek, AstraZeneca, Pfizer, Oxford immunotec, Inflazome, NGMBiopharmaceuticals, Uptodate, Cadilla pharmaceuticals.

To cite this abstract in AMA style:

Nakafero G, Grainge M, Card T, Taal M, Aithal G, Fox C, Mallen C, van der Windt D, Riley R, Abhishek A. Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-and-validation-of-a-prognostic-model-for-methotrexate-discontinuation-with-abnormal-monitoring-blood-test-results-a-cohort-study-using-data-from-clinical-practice-research-datalink-gold-a/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-of-a-prognostic-model-for-methotrexate-discontinuation-with-abnormal-monitoring-blood-test-results-a-cohort-study-using-data-from-clinical-practice-research-datalink-gold-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology